CSL Of Australia Raises Equity Funds Ahead of U.S. Merger Approval
This article was originally published in PharmAsia News
Australia's CSL drug maker has gone ahead with assertive equity-raising efforts even though the U.S. Federal Trade Commission could still block its planned $3.5 billion acquisition of Talecris Biotherapeutics. In less than a week after the deal was announced, CSL raised $1.53 billion to buy the firm from its owners, Cerberus Partners and Ampersand Ventures. Some analysts believe the FTC will order some divestments of human plasma products before approving the merger. One problem could be Talecris's Gamunex, with has a 24 percent market share, the same as CSL and its own products, amounting to a combined 48 percent compared with Baxter International's market-leading 35 percent. (Click here for more
You may also be interested in...
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.